New Trends in China’s Innovative Drug Review: Two Emerging Therapies Highlight the Future of Oncology and Precision Medicine

By:DengYue International Business Division

In recent years, China’s pharmaceutical regulatory system has significantly accelerated the review and approval process for innovative drugs. As international pharmaceutical companies and domestic biotech firms continue to increase their research and development investment, a growing number of globally promising therapies are entering China’s regulatory pipeline.

A global pharmaceutical supplier that has long focused on China’s innovative drug landscape—DengYueMed—has noted the recent application and review progress of two innovative drugs, BMS-986504 and GS3-007a Dry Suspension. These therapies represent two important directions in pharmaceutical innovation: precision oncology and pediatric medicine development.

These drugs not only reflect major trends in global pharmaceutical research but also highlight the increasingly important role of China’s pharmaceutical market within the global drug innovation ecosystem.

A New Target in Precision Oncology: The PRMT5 Inhibitor BMS-986504

Developed by Bristol Myers Squibb, BMS-986504 is a novel small-molecule targeted anticancer therapy designed to selectively inhibit PRMT5 enzyme activity.

PRMT5 (Protein Arginine Methyltransferase 5) is an important enzyme involved in RNA splicing and gene expression regulation. In many cancers—particularly tumors with MTAP gene deletion—PRMT5 activity becomes essential for tumor cell survival.

Research suggests that approximately 10–15% of solid tumors exhibit MTAP deletion, including:

● Non-small cell lung cancer (NSCLC)

● Pancreatic cancer

● Cholangiocarcinoma

● Mesothelioma

BMS-986504 works by inhibiting the PRMT5-MTA complex, leveraging a synthetic lethality mechanism to selectively eliminate cancer cells while minimizing effects on normal tissues.

Early clinical studies have demonstrated promising results. Among patients with MTAP-deleted non-small cell lung cancer, the drug achieved an objective response rate (ORR) of approximately 29% along with a high disease control rate.

This treatment strategy—targeting tumors defined by specific genetic alterations—represents a key direction in modern precision oncology. As molecular diagnostic technologies continue to expand, therapies such as PRMT5 inhibitors may play an increasingly important role across multiple cancer indications.

A New Option for Pediatric Infection Treatment: GS3-007a Dry Suspension

Drug development for pediatric patients has historically faced challenges such as limited formulations and insufficient clinical data. For this reason, regulatory agencies worldwide have increasingly encouraged innovation in pediatric medicines.

GS3-007a Dry Suspension, submitted by Changchun GeneScience Pharmaceutical, is classified in China as a Class 1 innovative chemical drug. The product is formulated as a dry suspension, which can be reconstituted with water before administration to form an oral liquid.

This dosage form offers several advantages:

● Flexible dosing based on body weight

● Easier swallowing for pediatric patients

● Improved medication adherence

In pediatric infection management, oral suspensions and dry suspensions are widely used internationally. As China continues to strengthen policy support for pediatric drug development, more pharmaceutical companies are focusing on child-specific formulations.

Effective pediatric medicines must address not only safety and efficacy, but also taste, convenience, and long-term adherence. The development of GS3-007a reflects a growing patient-centered approach in pharmaceutical innovation.

Two Major Trends in China’s Innovative Drug Development

The development directions represented by these two drugs highlight several important trends within China’s pharmaceutical industry.

1. Precision-Medicine-Driven Targeted Oncology

Targeted therapies based on genetic mutations or metabolic characteristics are becoming a central focus in cancer treatment. Drugs such as PRMT5 inhibitors targeting MTAP-deleted tumors represent the next generation of precision oncology strategies.

2. Accelerated Development of Pediatric Medicines

Pediatric drug development has long been a global challenge. In recent years, Chinese regulators have actively encouraged the development of child-specific formulations and innovative pediatric therapies, which is expected to attract more companies into the pediatric pharmaceutical sector.

Looking Ahead: Global Opportunities for China’s Innovative Drugs

As China’s drug development capabilities continue to expand, collaboration between domestic pharmaceutical companies and international drug developers is becoming increasingly common. China is not only one of the largest pharmaceutical markets in the world but is also gradually emerging as an important center for global drug innovation.

Within this evolving ecosystem, international pharmaceutical supply chain companies also play an important role. For example, DengYueMed closely monitors developments in China’s innovative drug sector and works to connect emerging therapies with global healthcare markets through pharmaceutical trade and drug supply services.

For the global pharmaceutical industry, China represents not only a significant commercial opportunity but also an increasingly important platform for scientific collaboration and medical innovation.